News articles about The Joint Corp. (NASDAQ:JYNT) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. The Joint Corp. earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.7289228291811 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- The Joint’s (JYNT) CEO Peter Holt on Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Joint Corp to Host Earnings Call (finance.yahoo.com)
- The Joint Corp. Reports Third Quarter 2017 Financial Results (finance.yahoo.com)
- The Joint Corp. (JYNT) Announces Quarterly Earnings Results (americanbankingnews.com)
- Laboratory Corporation of America Holdings (LH) versus The Joint Corp. (JYNT) Head to Head Analysis (americanbankingnews.com)
The Joint Corp. (JYNT) traded up $0.39 during mid-day trading on Tuesday, reaching $5.90. The company had a trading volume of 203,800 shares, compared to its average volume of 30,530. The Joint Corp. has a fifty-two week low of $1.96 and a fifty-two week high of $5.99. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 0.22.
The Joint Corp. (NASDAQ:JYNT) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The business had revenue of $6.55 million for the quarter, compared to analysts’ expectations of $6.28 million. The Joint Corp. had a negative return on equity of 94.08% and a negative net margin of 36.74%. analysts forecast that The Joint Corp. will post -0.3 EPS for the current year.
JYNT has been the topic of several recent research reports. Maxim Group restated a “buy” rating and issued a $7.00 price target on shares of The Joint Corp. in a research note on Friday, August 11th. Roth Capital assumed coverage on The Joint Corp. in a research report on Thursday, July 27th. They issued a “buy” rating and a $5.70 price objective on the stock. Finally, Zacks Investment Research cut The Joint Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $5.86.
The Joint Corp. Company Profile
The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.
Receive News & Ratings for The Joint Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Joint Corp. and related companies with MarketBeat.com's FREE daily email newsletter.